Drug Profile
Research programme: serine protease inhibitors - viDA Therapeutics
Alternative Names: V-2248; VT-1002Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator viDA Therapeutics
- Class Biological proteins; Small molecules
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Discoid lupus erythematosus; Fibrosis; Rheumatoid arthritis; Skin disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Discoid-lupus-erythematosus in Canada (Topical, Cream)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-disorders in Canada (Topical)
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in Canada